Effect of aspirin on short-term outcomes in hospitalized patients with COVID-19-Reference-Cited by-同舟云学术

Effect of aspirin on short-term outcomes in hospitalized patients with COVID-19

Published:2021-05-19 Issue:6 Volume:26 Page:626-632
ISSN:1358-863X
Container-title:Vascular Medicine
language:en
Short-container-title:Vasc Med

Author:

Sahai Aditya¹,Bhandari Rohan¹²^ORCID,Godwin Matthew²,McIntyre Thomas²,Chung Mina K²³,Iskandar Jean-Pierre⁴,Kamran Hayaan¹,Hariri Essa⁴,Aggarwal Anu²,Burton Robert⁴,Kalra Ankur¹,Bartholomew John R¹,McCrae Keith R³⁵,Elbadawi Ayman⁶^ORCID,Bena James⁷,Svensson Lars G¹,Kapadia Samir¹,Cameron Scott J¹²⁵^ORCID

Affiliation:

1. Section of Vascular Medicine, Department of Cardiovascular Medicine; Heart, Vascular & Thoracic Institute, Cleveland Clinic, Cleveland, OH, USA

2. Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA

3. Department of Cardiovascular Medicine; Heart, Vascular & Thoracic Institute, Cleveland Clinic, Cleveland, OH, USA

4. Department of Internal Medicine, Cleveland Clinic, Cleveland, OH, USA

5. Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA

6. Division of Cardiovascular Medicine, University of Texas Medical Branch, Galveston, TX, USA

7. Department of Quantitative Health Science, Cleveland Clinic, Cleveland, OH, USA

Abstract

Coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2 is an ongoing viral pandemic marked by increased risk of thrombotic events. However, the role of platelets in the elevated observed thrombotic risk in COVID-19 and utility of antiplatelet agents in attenuating thrombosis is unknown. We aimed to determine if the antiplatelet effect of aspirin may mitigate risk of myocardial infarction, cerebrovascular accident, and venous thromboembolism in COVID-19. We evaluated 22,072 symptomatic patients tested for COVID-19. Propensity-matched analyses were performed to determine if treatment with aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) affected thrombotic outcomes in COVID-19. Neither aspirin nor NSAIDs affected mortality in COVID-19. Thus, aspirin does not appear to prevent thrombosis and death in COVID-19. The mechanisms of thrombosis in COVID-19, therefore, appear distinct and the role of platelets as direct mediators of SARS-CoV-2-mediated thrombosis warrants further investigation.

Funder

National Heart, Lung, and Blood Institute

Publisher

SAGE Publications

Subject

Cardiology and Cardiovascular Medicine

Link

http://journals.sagepub.com/doi/pdf/10.1177/1358863X211012754

Reference49 articles.

1. Incidence of thrombotic complications in critically ill ICU patients with COVID-19

2. Risk of Ischemic Stroke in Patients With Coronavirus Disease 2019 (COVID-19) vs Patients With Influenza

3. High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study